FR2619715A1 - Isosmotic polyionic glucose solution - Google Patents
Isosmotic polyionic glucose solution Download PDFInfo
- Publication number
- FR2619715A1 FR2619715A1 FR8712101A FR8712101A FR2619715A1 FR 2619715 A1 FR2619715 A1 FR 2619715A1 FR 8712101 A FR8712101 A FR 8712101A FR 8712101 A FR8712101 A FR 8712101A FR 2619715 A1 FR2619715 A1 FR 2619715A1
- Authority
- FR
- France
- Prior art keywords
- gram
- magnesium
- milliliters
- grams
- polyionic
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/14—Alkali metal chlorides; Alkaline earth metal chlorides
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Inorganic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
DESCRIPTION
Le titre de l'invention est : SOLUTE DE PERFUSION INTRA-VEINEUSE, SERUM
GLUCOSE POL YIONIQUE ISO-OSMOTIQUE. DESCRIPTION
The title of the invention is: INTRAVENOUS PERFUSION SOLUTE, SERUM
ISO-OSMOTIC POL YIONIC GLUCOSE.
La présente invention concerne un soluté de perfusion intra-veineuse destiné à compenser des pertes hydriques, minimes ou massives, en maintenant chez ces patients un équilibre homéostasique.The present invention relates to an intravenous infusion solution intended to compensate for minimal or massive fluid losses, by maintaining in these patients a homeostatic balance.
Le domaine technique de l'invention correspond aux indications de perfusion intra-veineuse de solutés polyioniques, apyrogènes, stériles, iso-osmotiques au plasma chez tous les patients ne pouvant, du fait de leur affection, assurer par eux mêmes leur équilibre homéostasique.The technical field of the invention corresponds to the indications for intravenous infusion of polyionic, pyrogen-free, sterile, iso-osmotic plasma solutions in all patients who cannot, by reason of their affection, ensure by themselves their homeostatic balance.
Le soluté de l'invention se différencie des solutés pré-existants par sa parfaite tolérance lors de perfusions massives : pouvant être supérieures à 10 litres par 24 heures. Ceci n 'est pas réalisable avec les solutés pré-existants. En effet
- le sérum glucosé isotonique à 5 Q entraîne un apport d'hydrates de carbone trop important lorsqu 'il existe des perturbations de la glyco régulation (exemple : diabète) ; il peut générer dans d'autres cas de for- tes hypo-osmolarités plasmatiques.The solute of the invention differs from pre-existing solutes by its perfect tolerance during massive infusions: which can be greater than 10 liters per 24 hours. This is not possible with pre-existing solutions. Indeed
- the 5Q isotonic glucose serum leads to too much carbohydrate intake when there are disturbances in glyco regulation (example: diabetes); in other cases, it can generate strong plasma hypo-osmolarities.
- le sérum salé isotonique à 0, 9 10 : la charge sodée qui 1 'accompagne le contre-indique chez le cardiaque, 1 'hypertendu, I 1insuffisant rénal ; il est dépourvu de substrat énergétique. - the saline isotonic at 0.99 10: the sodium charge which accompanies it cons-indicates in the cardiac, hypertensive, I 1 insufficient renal; it has no energy substrate.
- les solutés polyioniques normo-osmotiques déjà existants diffèrent de 1 'invention par leur contenu en sels de potassium qui les contre-indiquent lors de 1 'emploi massif ou chez le patient en insuffisance rénale. - the already existing normo-osmotic polyionic solutions differ from the invention by their potassium salt content which contraindicates them during massive use or in patients with renal insufficiency.
La présente invention est un soluté comportant du glucose, à faible concentration et des ions. II correspond à la formule suivante : chlorure de sodium = 4 grammes ; carbonate monosodique à 4,2 % = 40 mil lilitres ; gluconate de calcium à 10 Ao: : 0,5 grammes ; sérum glucosé hypo- tonique à 2,5 ia = QSP 1 000 millilitres. The present invention is a solute comprising glucose, at low concentration and ions. It corresponds to the following formula: sodium chloride = 4 grams; 4.2% monosodium carbonate = 40 mil lilitres; calcium gluconate at 10 Ao:: 0.5 grams; 2.5 ton hypotonic glucose serum = QSP 1000 milliliters.
Une variante de cette solution est caractérisée par : chlorure de sodium = 3 grammes ; carbonate monosodique à 4,2 50 = 60 millilitres ; gluconate de calcium à 10 Q = 0,5 grammes ; pyrrolidone carboxylate de magnésium à 10 % = 0,5 grammes ; sérum glucosé hypotonique à 2,5 % : QSP pour 1 000 millilitres. Le soluté est iso-osmotique au plasma ; il est étudié de telle
sorte que sa tolérance est parfaite, employé massivement (10 litres par 24
heures) et! ou à débit massif (supérieur à 1 litre par heure). L'équilibre hydro-électrolytique et osmotique plasmatique des patients est respecté qu que soit leur état pathologique : intolérance glucidique, insuffisance réa; cardiaque, acidoses métaboliques. Cet équilibre est également respecté en pit des perturbations occasionnées par la corticothérapie, les diurétiques, les pertes digestives de toutes sortes. Ce soluté comporte du chlorure de dium, du bicarbonate monosodique de sodium, du gluconate de calcium, d magnésium. Une variante de cette invention comporte : une plus forte con tration de bicarbonate monosodique de sodium, elle est plus adéquate dan les cas d 'acidoses métaboliques. Les composants de ce soluté sont disponi
sur le marché, répondant aux critères de solutés appropriés aux perfusa
intra-veineuses ; leur association ne modifie en rien leurs qualités (y co
pris leur conservation).A variant of this solution is characterized by: sodium chloride = 3 grams; 4.2 50 monosodium carbonate = 60 milliliters; calcium gluconate at 10 Q = 0.5 grams; 10% magnesium pyrrolidone carboxylate = 0.5 grams; 2.5% hypotonic glucose serum: QSP per 1000 milliliters. The solute is iso-osmotic to plasma; it is studied in such a way
so that its tolerance is perfect, used massively (10 liters per 24
hours) and! or at massive flow (greater than 1 liter per hour). The plasma hydro-electrolytic and osmotic balance of patients is respected whatever their pathological state: carbohydrate intolerance, shortage of shea; cardiac, metabolic acidosis. This balance is also respected in the pit of disturbances caused by corticosteroid therapy, diuretics, digestive losses of all kinds. This solute contains dium chloride, sodium bicarbonate sodium, calcium gluconate, magnesium. A variant of this invention comprises: a higher con tration of sodium bicarbonate sodium, it is more adequate in cases of metabolic acidosis. The components of this solute are available.
on the market, meeting the criteria of solutions suitable for perfusa
intravenous; their association in no way changes their qualities (including
took their conservation).
La préparation du soluté est longue, fait encourir des risques
septicité, ce qui augmente l'intérêt d'une fabrication industrielle. Solute preparation takes a long time, involves risks
septicity, which increases the interest of industrial manufacturing.
Claims (1)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR8712101A FR2619715A1 (en) | 1987-08-25 | 1987-08-25 | Isosmotic polyionic glucose solution |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR8712101A FR2619715A1 (en) | 1987-08-25 | 1987-08-25 | Isosmotic polyionic glucose solution |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| FR2619715A1 true FR2619715A1 (en) | 1989-03-03 |
Family
ID=9354522
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| FR8712101A Withdrawn FR2619715A1 (en) | 1987-08-25 | 1987-08-25 | Isosmotic polyionic glucose solution |
Country Status (1)
| Country | Link |
|---|---|
| FR (1) | FR2619715A1 (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1996020719A2 (en) * | 1994-12-30 | 1996-07-11 | The East And Midlothian Nhs Trust | Body fluid replacement solution |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2380028A1 (en) * | 1977-02-10 | 1978-09-08 | Cotte Jean Marie | Solns. for enteral or parenteral feeding - contg. calcium component and masked phosphate component |
| US4308255A (en) * | 1980-03-24 | 1981-12-29 | Haemophor Corporation | Balanced oncotic pressure fluid |
| WO1987003808A1 (en) * | 1985-12-18 | 1987-07-02 | Veech Richard L | Fluid therapy with l-lactate and/or pyruvate anions |
-
1987
- 1987-08-25 FR FR8712101A patent/FR2619715A1/en not_active Withdrawn
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2380028A1 (en) * | 1977-02-10 | 1978-09-08 | Cotte Jean Marie | Solns. for enteral or parenteral feeding - contg. calcium component and masked phosphate component |
| US4308255A (en) * | 1980-03-24 | 1981-12-29 | Haemophor Corporation | Balanced oncotic pressure fluid |
| WO1987003808A1 (en) * | 1985-12-18 | 1987-07-02 | Veech Richard L | Fluid therapy with l-lactate and/or pyruvate anions |
Non-Patent Citations (1)
| Title |
|---|
| CHEMICAL ABSTRACTS, vol. 103, 1985, page 58, no. 581k, Columbus, Ohio, US; S.MATSUMOTO et al.: "Effects of various irrigating solutions on the blood-aqueous barrier of the canine eye" & ATARASHII GANKA 1984, 1(1), 129-31 * |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1996020719A2 (en) * | 1994-12-30 | 1996-07-11 | The East And Midlothian Nhs Trust | Body fluid replacement solution |
| WO1996020719A3 (en) * | 1994-12-30 | 1996-09-06 | East And Midlothian Nhs Trust | Body fluid replacement solution |
| US5846572A (en) * | 1994-12-30 | 1998-12-08 | East & Midlothian Nhs Trust | Body fluid replacement solution |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Orofino et al. | Epidemiology of symptomatic hypotension in hemodialysis: is cool dialysate beneficial for all patients? | |
| McIntyre | Effects of hemodialysis on cardiac function | |
| Ginès et al. | Incidence, predictive factors, and prognosis of the hepatorenal syndrome in cirrhosis with ascites | |
| Hilberman et al. | Sequential pathophysiological changes characterizing the progression from renal dysfunction to acute renal failure following cardiac operation | |
| US4308255A (en) | Balanced oncotic pressure fluid | |
| Schurek et al. | The basic requirements for the function of the isolated cell free perfused rat kidney | |
| Ekins et al. | Standardized treatment of severe methanol poisoning with ethanol and hemodialysis | |
| Arroyo | albumin in the treatment of liver diseases—new features of a classical treatment | |
| FR2619715A1 (en) | Isosmotic polyionic glucose solution | |
| Barton et al. | Renal pathology in end-stage renal disease associated with paraplegia | |
| Goritsas et al. | Intrahepatic bile duct injury and nodular regenerative hyperplasia of the liver in a patient with polyarteritis nodosa | |
| Klauwers et al. | Failure of Renal Transplantation in Primary Oxalosisn | |
| WO2001047576A3 (en) | Compositions for replacement fluid and associated systems and methods usable in the performance of frequent hemofiltration | |
| McIver | A study in extensive cutaneous burns | |
| Raju et al. | The effects of dialytic ultrafiltration and peritoneal reinfusion in the management of diuretic resistant ascites. | |
| Rush et al. | Limits of non-colloid solution replacement in experimental hemorrhagic shock. | |
| Hans et al. | Effects of 1.5% glycine solution with and without 1% ethanol on the fluid balance in elderly men | |
| Weis et al. | “TUR syndrome” after transurethral resection of the prostate using suprapubic drainage | |
| Smith et al. | Treatment of Raynaud's phenomenon with calcium channel blockers | |
| Adams et al. | Technique and experience using potassium cardioplegia during myocardial revascularization for preinfarction angina | |
| Barlow, RJ, Connell, MA, Levendig, BJ, Gear, JSS & Milne | A comparative study of urinary sodium and potassium excretion in normotensive urban black and white South African males | |
| Molloy et al. | Left main stem coronary artery dissection. | |
| Sonobe et al. | Spontaneous rupture of the spleen in acute myeloid leukemia | |
| Abbott et al. | Metabolic Alterations Following Thermal Burns: V. The use of Whole Blood and an Electrolyte Solution in the Treatment of Burned Patients | |
| Beal et al. | Consequences of fluid absorption during transurethral resection of the prostate using distilled water or glycine 1.5 per cent |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| ST | Notification of lapse | ||
| AR | Application made for restoration | ||
| BR | Restoration of rights | ||
| ST | Notification of lapse |